Resolution of gastrointestinal side effects in a patient converted from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®)

Drugs

Volumn 66, Issue SUPPL. 2, 2006, Pages 9-10

  Tuncer, Murat ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; DACLIZUMAB; FAMOTIDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

ADULT; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG SUBSTITUTION; DYSPEPSIA; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCELE; MALE; NAUSEA; URINARY TRACT INFECTION; VESICOURETERAL REFLUX;

EID: 33751539416     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666002-00003     Document Type: Article

References (2)

1. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381-6
2. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200-5